Symbion Capitulates, Nearing End To Primary’s Takeover Of Australian Health Care Giant
This article was originally published in PharmAsia News
The months-long battle between Australia's giant health care companies appeared near an end when Primary Healthcare said it had won control of a majority of Symbion Healthcare. The Symbion board capitulated in the battle and recommended shareholders accept the buyout when Primary gained 50.1 percent of the shares. Among the businesses at sake is Symbion's pharmacy business. (Click here for more
You may also be interested in...
US FDA investigators are more likely to cite cell and gene therapy manufacturers for facilities and production deficiencies, agency says, while industry reports difficulties complying with drug GMP requirements that are not always applicable to cell and gene therapies.
GSK’s antibody-drug conjugate may reach the market first, but CAR-T therapies from Bristol/bluebird and Janssen/Legend are close behind, and all three big pharmas have programs in earlier-stage disease.
Manufacturers warned to keep better electronic records and not falsify data in recent warning letters, ICH adds three residual solvent limits for pharmaceuticals, and the Polish authority hits firm for GMP noncompliance.